GSK2556286   Click here for help

GtoPdb Ligand ID: 13078

Synonyms: GSK286
Compound class: Synthetic organic
Comment: GSK2556286 is a substituted 4-aryloxypiperidine identified from a screen of compounds that inhibit intracellular growth of Mycobacterium tuberculosis in human macrophage-like differentiated monocytes (THP-1 cell line) [2]. It has a novel cholesterol-dependent mechanism of action, with recent studies establishing it as an agonist of mycobacterial Rv1625c, a membrane-bound adenylyl cyclase [1-2]. GSK2556286 is under clinical development as a potential treatment for tuberculosis (TB).
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 4
Topological polar surface area 70.67
Molecular weight 329.39
XLogP 1.06
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC1=CC=CC(=C1C)OC2CCN(CC2)CC3=CC(=O)NC(=O)N3
Isomeric SMILES CC1=C(C(=CC=C1)OC2CCN(CC2)CC3=CC(=O)NC(=O)N3)C
InChI InChI=1S/C18H23N3O3/c1-12-4-3-5-16(13(12)2)24-15-6-8-21(9-7-15)11-14-10-17(22)20-18(23)19-14/h3-5,10,15H,6-9,11H2,1-2H3,(H2,19,20,22,23)
InChI Key AZOFJHATIPDIER-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
A first-in-human safety, tolerability and pharmacokinetics study, evaluating GSK2556286 in healthy adult participants, began in October 2020 (NCT04472897).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04472897 A Study to Evaluate Safety, Tolerability and Pharmacokinetics of GSK2556286 in Healthy Adult Participants Phase 1 Interventional GlaxoSmithKline